Your browser doesn't support javascript.
loading
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.
Szarewski, Anne; Skinner, S Rachel; Garland, Suzanne M; Romanowski, Barbara; Schwarz, Tino F; Apter, Dan; Chow, Song-Nan; Paavonen, Jorma; Del Rosario-Raymundo, M Rowena; Teixeira, Julio C; De Carvalho, Newton S; Castro-Sanchez, Maria; Castellsagué, Xavier; Poppe, Willy A J; De Sutter, Philippe; Huh, Warner; Chatterjee, Archana; Tjalma, Wiebren A; Ackerman, Ronald T; Martens, Mark; Papp, Kim A; Bajo-Arenas, Jose; Harper, Diane M; Torné, Aureli; David, Marie-Pierre; Struyf, Frank; Lehtinen, Matti; Dubin, Gary.
Afiliación
  • Szarewski A; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, United Kingdom.
J Infect Dis ; 208(9): 1391-6, 2013 Nov 01.
Article en En | MEDLINE | ID: mdl-24092907
BACKGROUND: Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent. METHODS: Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations. RESULTS: In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV-6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74. CONCLUSIONS: The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Condiloma Acuminado / Adyuvantes Inmunológicos / Vacunación / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Hidróxido de Aluminio / Lípido A Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: J Infect Dis Año: 2013 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Condiloma Acuminado / Adyuvantes Inmunológicos / Vacunación / Papillomavirus Humano 16 / Papillomavirus Humano 18 / Hidróxido de Aluminio / Lípido A Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: J Infect Dis Año: 2013 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos